Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (51-60 of 187) with videos related to

Pageof 19
Sort By:
Anticancer Research|November 24, 2011
Ethnic differences in neuroendocrine expression in prostate cancer tissueTanya B Dorff, Stephen V Liu, Shigang Xiong, et al.
Expert Opinion on Emerging Drugs|December 21, 2013
Emerging protein kinase inhibitors for non-small cell lung cancerStephen V Liu, Deepa Subramaniam, George C Cyriac, et al.
Journal of Hematology & Oncology|October 26, 2022
Drugging KRAS: current perspectives and state-of-art reviewKaushal Parikh, Giuseppe Banna, Stephen V Liu, et al.
Immunotherapy|October 17, 2025
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLCStephen V Liu, Riddhi A Babel, Yu-Han Kao, et al.
Clinical Lung Cancer|June 16, 2024
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLCVamsidhar Velcheti, Pragya Rai, Yu-Han Kao, et al.
The Oncologist|April 12, 2021
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung CancerMonica Peravali, Jaeil Ahn, Kevin Chen, et al.
JTO Clinical and Research Reports|April 14, 2025
Discordant Response to Nivolumab Plus Ipilimumab and Identification of <i>BRAF</i> V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case ReportOlivia Wilkins, Adedamola Omogbehin, Peter J Bergquist, et al.
Frontiers in Oncology|March 30, 2018
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung CancerDeepa S Subramaniam, Stephen V Liu, Jeanette Crawford, et al.
JCO Precision Oncology|January 7, 2022
Divergent <i>RET</i>- and <i>BRAF</i>-Mediated Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC: A Case ReportMuneeb Rehman, Chul Kim, Joshua E Reuss, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Phase I study of the <sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lungChul Kim, Stephen V Liu, Deepa S Subramaniam, et al.
Pageof 19

Showing results (51-60 of 187) with videos related to

Sort By:
Pageof 19
Anticancer Research|November 24, 2011
Ethnic differences in neuroendocrine expression in prostate cancer tissueTanya B Dorff, Stephen V Liu, Shigang Xiong, et al.
Expert Opinion on Emerging Drugs|December 21, 2013
Emerging protein kinase inhibitors for non-small cell lung cancerStephen V Liu, Deepa Subramaniam, George C Cyriac, et al.
Journal of Hematology & Oncology|October 26, 2022
Drugging KRAS: current perspectives and state-of-art reviewKaushal Parikh, Giuseppe Banna, Stephen V Liu, et al.
Immunotherapy|October 17, 2025
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLCStephen V Liu, Riddhi A Babel, Yu-Han Kao, et al.
Clinical Lung Cancer|June 16, 2024
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLCVamsidhar Velcheti, Pragya Rai, Yu-Han Kao, et al.
The Oncologist|April 12, 2021
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung CancerMonica Peravali, Jaeil Ahn, Kevin Chen, et al.
JTO Clinical and Research Reports|April 14, 2025
Discordant Response to Nivolumab Plus Ipilimumab and Identification of <i>BRAF</i> V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case ReportOlivia Wilkins, Adedamola Omogbehin, Peter J Bergquist, et al.
Frontiers in Oncology|March 30, 2018
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung CancerDeepa S Subramaniam, Stephen V Liu, Jeanette Crawford, et al.
JCO Precision Oncology|January 7, 2022
Divergent <i>RET</i>- and <i>BRAF</i>-Mediated Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC: A Case ReportMuneeb Rehman, Chul Kim, Joshua E Reuss, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Phase I study of the <sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lungChul Kim, Stephen V Liu, Deepa S Subramaniam, et al.
Pageof 19